Johnson & Johnson’s single-dose COVID-19 vaccine gets Emergency Use approval in India


PTI, Aug 7, 2021, 2:42 PM IST

 

New Delhi: Johnson & Johnson’s single-dose COVID-19 vaccine has been given Emergency Use approval in India, Union Health minister Mansukh Mandaviya said on Saturday.

He said this will further boost the country’s collective fight against the novel coronavirus infection.

“India expands its vaccine basket! Johnson and Johnson’s single-dose COVID-19 vaccine is given approval for Emergency Use in India. Now India has five EUA vaccines. This will further boost our nation’s collective fight against #COVID19,” the minister tweeted.

“The US-based pharmaceutical company had applied for Emergency Use Authorisation for its jab on Friday and was granted the approval the same day by the Drugs Controller General of India (DCGI),” a senior official said.

The five vaccines granted Emergency Use Authorisation in India are Serum Institute’s Covishield, Bharat Biotech’s Covaxin, Russia’s Sputnik V, Moderna and now Johnson & Johnson (J&J).

J&J earlier had sought approval to conduct phase-3 clinical trial of its vaccine on approximately 600 participants in two age groups—those aged 18 and below 60 years and those aged 60 years and above—to evaluate the safety, reactogenicity and immunogenicity of the jab in healthy Indian adults.

However, on July 29, the firm withdrew its proposal.

A health ministry official at a recent press conference had clarified that J&J earlier applied for conducting phase-3 clinical trial of its vaccine.

“The application was to undertake clinical trial and when we issued relaxed guidelines in which we said if you had approval from other regulatory bodies of other countries, then exemption would be given from clinical trials, and emergency use authorisation would be granted and trial could be continued later on, so now since they did not need it they withdrew that application,” the official had said.

In a bid to fast-track emergency approvals for all foreign-produced coronavirus jabs, the central government had announced that COVID-19 vaccines which were approved for restricted use by regulators in the US, UK, Europe and Japan, or which were on the World Health Organisation’s Emergency Use Listing, would not have to conduct bridging clinical trials in India.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Haridwar Dharma Sansad case: SC extends interim bail to hate speech accused

PM Modi attends special screening of TV show on Indian history’s lesser-known tales

I was out for 2 months but team hasn’t forgotten what I have done for 2 years: KL Rahul

Petrol, diesel demand to grow: India’s oil requirement to rise 7.7% in 2022, says OPEC

SC seeks response of Centre, poll panel on PIL seeking voting rights for NRIs

Madhavan on ‘Laal Singh…’ box office performance: It’s going to take us time to pull up our socks

Now, taste local flavours as vendors return on trains


Related Articles More

Haridwar Dharma Sansad case: SC extends interim bail to hate speech accused

Delhi double murder: Family friend who borrowed Rs 4 lakh arrested

PM Modi attends special screening of TV show on Indian history’s lesser-known tales

Continued killings of KPs utter failure of the LG administration: BJP in Kashmir

SC seeks response of Centre, poll panel on PIL seeking voting rights for NRIs

MUST WATCH

Why young men and women mostly become drug addicts?

NEWS BULLETIN 17-08-2022

NEWS BULLETIN 16-08-2022

Independenceday function

Congress Freedom March


Latest Additions

Haridwar Dharma Sansad case: SC extends interim bail to hate speech accused

Delhi double murder: Family friend who borrowed Rs 4 lakh arrested

PM Modi attends special screening of TV show on Indian history’s lesser-known tales

I was out for 2 months but team hasn’t forgotten what I have done for 2 years: KL Rahul

Petrol, diesel demand to grow: India’s oil requirement to rise 7.7% in 2022, says OPEC

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.